A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus First in man; Pharmacokinetics; Registrational
- Sponsors Amgen
- 15 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Aug 2017 Planned End Date changed from 2 Aug 2018 to 2 Oct 2018.
- 24 Aug 2017 Planned primary completion date changed from 29 Mar 2018 to 29 May 2018.